Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
11.6M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
279K
-
Shares change
-
+28.5K
-
Total reported value, excl. options
-
$490K
-
Value change
-
+$50.2K
-
Number of buys
-
5
-
Price
-
$1.76
Significant Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q2 2025
6 filings reported holding APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock as of Q2 2025.
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 279K shares
of 11.6M outstanding shares and own 2.41% of the company stock.
Largest 6 shareholders include Yorkville Advisors Global, LP (250K shares), CITADEL ADVISORS LLC (13.4K shares), GOLDMAN SACHS GROUP INC (12K shares), Tower Research Capital LLC (TRC) (3.15K shares), BANK OF AMERICA CORP /DE/ (29 shares), and JPMORGAN CHASE & CO (5 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.